Rocket Pharmaceuticals Files 8-K
Ticker: RCKTW · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials
TL;DR
Rocket Pharma filed an 8-K, mostly financial docs, no big news.
AI Summary
On August 20, 2025, Rocket Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely containing financial statements and exhibits, but does not disclose any new material events.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not contain information about significant risks or material events.
Key Players & Entities
- ROCKET PHARMACEUTICALS, INC. (company) — Registrant
- INOTEK PHARMACEUTICALS CORP (company) — Former company name
- August 20, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for reporting financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
What is the exact name of the company filing this report?
The exact name of the registrant is Rocket Pharmaceuticals, Inc.
In which state was Rocket Pharmaceuticals, Inc. incorporated?
Rocket Pharmaceuticals, Inc. was incorporated in Delaware.
What was the former name of Rocket Pharmaceuticals, Inc.?
The former name of the company was INOTEK PHARMACEUTICALS CORP.
What is the principal executive office address for Rocket Pharmaceuticals, Inc.?
The address of the principal executive offices is 9 Cedarbrook Drive, Cranbury, NJ 08512.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-08-20 07:11:02
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20054253_8k.htm (8-K) — 28KB
- ef20054253_ex99-1.htm (EX-99.1) — 21KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-25-032012.txt ( ) — 186KB
- rckt-20250820.xsd (EX-101.SCH) — 4KB
- rckt-20250820_lab.xml (EX-101.LAB) — 21KB
- rckt-20250820_pre.xml (EX-101.PRE) — 16KB
- ef20054253_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On August 20, 2025, Rocket Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration has lifted the clinical hold on the Company's pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this report by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated August 20, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: August 20, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP